Journal content

The Journal of Clinical Sleep Medicine publication shows

Study Finds ProSomnus Precision Oral Appliance Therapy Devices Offer Comparable Efficacy to CPAP for Mild and Moderate OSAS

Precision oral therapeutic devices represent a new category of intraoral medical devices for the treatment of OSA

SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies (“ProSomnus”), the leader in patient-preferred medical devices for the treatment of obstructive sleep apnea (OSA), today announced the results of a peer-reviewed study published by the Journal of Clinical Sleep Medicine (JCSM)who discovered that ProSomnus’ precision oral therapy devices (OATs) successfully treated OSAS in most patients.

In a prospective, blinded study of 58 people with OSA, researchers sought to determine the predictive accuracy of Zephyr Sleep Technologies’ MATRx plus™ mandibular repositioning test, as well as the therapeutic efficacy of the ProSomnus precision OAT device and its ability to resolve the symptoms of OSA. . The ProSomnus Precision OAT device uses proprietary technologies to replicate the bite position provided by the MATRx plus test.

Key findings from the study include:

  • 94% of patients with mild and moderate OSA were successfully treated with ProSomnus Precision OAT (based on a success criterion of oxygen desaturation index -1)
  • 81% of patients of all severities were successfully treated with ProSomnus Precision OAT
  • 97% of patients reported a reduction in snoring (median reduction of six points on a 10-point scale)
  • 69% of patients reported feeling an improvement in sleep quality (median improvement of four points on a 10-point scale)
  • 85% of patients reported reaching their treatment goal

“OSA continues to be a major unmet medical need worldwide. Standard therapies such as CPAP often result in low compliance due to their invasive nature,” said John E. Remmers, MD, chief scientist of ProSomnus Sleep Technologies. “This study indicates that ProSomnus’ precision and mass-customized oral therapy devices are highly effective in the treatment of mild to moderate OSA and can greatly benefit patients and provide a less invasive solution for those suffering from OSA. .”

“Healthcare providers cite poor and uncertain efficacy as the reason they are reluctant to prescribe traditional OAT devices, even for patients who refuse or fail CPAP,” added Len Liptak, CEO of ProSomnus Sleep Technologies. “This investigation adds to a growing body of clinical data indicating that precision OAT devices, a new class of intraoral medical devices that reposition and stabilize the patient’s mandible with greater precision, alleviate these concerns by providing a more predictable, consistent and effective treatment.”

About OSA

OSA is the recurrent collapse of the airways during sleep, leading to oxygen shortages and abrupt awakenings with gasping or choking. In addition to daytime sleepiness, OSA is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. Patients with OSA not treated are 23 times more likely to suffer a heart attack and four times more likely to have a stroke. It is estimated that over one billion people worldwide and over 74 million people in North America suffer from OSA. About 56 million of those 74 million people in North America are undiagnosed.

About ProSomnis Sleep Technologies

ProSomnus is the leading manufacturer of precision, personalized oral therapy devices (OATs) to treat obstructive sleep apnea, which affects more than 74 million Americans and is associated with serious comorbidities including heart failure, stroke, hypertension, morbid obesity and type 2. Diabetes. ProSomnus’ patented devices are a more comfortable and less invasive alternative to continuous positive airway pressure (CPAP) therapy and lead to more effective and patient-preferred results. With more than 135,000 patients treated, ProSomnus devices are the most prescribed OATs in the United States. To learn more, visit


Sean Leous
[email protected]

Mike Cavanaugh
[email protected]